These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 23442835

  • 1. Obesity does not affect treatment outcomes with proton pump inhibitors.
    Sharma P, Vakil N, Monyak JT, Silberg DG.
    J Clin Gastroenterol; 2013 Sep; 47(8):672-7. PubMed ID: 23442835
    [Abstract] [Full Text] [Related]

  • 2. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Sharma P, Johnson DA, Monyak JT, Illueca M.
    Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
    [Abstract] [Full Text] [Related]

  • 3. Heartburn severity does not predict disease severity in patients with erosive esophagitis.
    Fennerty MB, Johnson DA.
    MedGenMed; 2006 Apr 06; 8(2):6. PubMed ID: 16926745
    [Abstract] [Full Text] [Related]

  • 4. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
    Peura DA, Pilmer B, Hunt B, Mody R, Perez MC.
    Aliment Pharmacol Ther; 2013 Apr 06; 37(8):810-8. PubMed ID: 23451835
    [Abstract] [Full Text] [Related]

  • 5. Predictors of heartburn resolution and erosive esophagitis in patients with GERD.
    Orlando RC, Monyak JT, Silberg DG.
    Curr Med Res Opin; 2009 Sep 06; 25(9):2091-102. PubMed ID: 19601705
    [Abstract] [Full Text] [Related]

  • 6. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
    Peura DA, Pilmer B, Hunt B, Mody R, Perez MC.
    Aliment Pharmacol Ther; 2013 Nov 06; 38(10):1303-11. PubMed ID: 24118079
    [Abstract] [Full Text] [Related]

  • 7. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P, van Zanten SV, Mattsson H, Wernersson B.
    Aliment Pharmacol Ther; 2012 Oct 06; 36(7):635-43. PubMed ID: 22860764
    [Abstract] [Full Text] [Related]

  • 8. Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
    Pace F, Coudsy B, DeLemos B, Sun Y, Xiang J, LoCoco J, Casalini S, Li H, Pelosini I, Scarpignato C.
    Eur J Gastroenterol Hepatol; 2011 Oct 06; 23(10):845-51. PubMed ID: 21900784
    [Abstract] [Full Text] [Related]

  • 9. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
    Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y.
    Aliment Pharmacol Ther; 2011 Jan 06; 33(2):203-12. PubMed ID: 21114792
    [Abstract] [Full Text] [Related]

  • 10. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
    Hongo M, Miwa H, Kusano M, J-FAST group.
    J Gastroenterol Hepatol; 2012 May 06; 27(5):913-8. PubMed ID: 22142515
    [Abstract] [Full Text] [Related]

  • 11. Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study.
    Nocon M, Labenz J, Jaspersen D, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P, Willich SN.
    J Gastroenterol Hepatol; 2007 Nov 06; 22(11):1728-31. PubMed ID: 17914941
    [Abstract] [Full Text] [Related]

  • 12. Refractory GERD: increased body mass index is associated with persisting acid exposure but not hypersensitive esophagus or functional heartburn.
    Viazis N, Karamanolis GP, Anastasiou J, Keyoglou A, Vlachogiannakos J, Ladas SD, Karamanolis DG.
    Eur J Gastroenterol Hepatol; 2013 Dec 06; 25(12):1450-5. PubMed ID: 24047861
    [Abstract] [Full Text] [Related]

  • 13. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, Damico D, Hamelin B.
    Am J Gastroenterol; 2001 Jan 06; 96(1):27-34. PubMed ID: 11197282
    [Abstract] [Full Text] [Related]

  • 14. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
    Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG.
    Am J Gastroenterol; 2002 Mar 06; 97(3):575-83. PubMed ID: 11922549
    [Abstract] [Full Text] [Related]

  • 15. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
    Emerson CR, Marzella N.
    Clin Ther; 2010 Aug 06; 32(9):1578-96. PubMed ID: 20974316
    [Abstract] [Full Text] [Related]

  • 16. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment.
    Poh CH, Gasiorowska A, Navarro-Rodriguez T, Willis MR, Hargadon D, Noelck N, Mohler J, Wendel CS, Fass R.
    Gastrointest Endosc; 2010 Jan 06; 71(1):28-34. PubMed ID: 19922918
    [Abstract] [Full Text] [Related]

  • 17. Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
    Yaghoobi M, Padol S, Yuan Y, Hunt RH.
    Eur J Gastroenterol Hepatol; 2010 May 06; 22(5):583-90. PubMed ID: 20061959
    [Abstract] [Full Text] [Related]

  • 18. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
    Wu JC, Lai LH, Chow DK, Wong GL, Sung JJ, Chan FK.
    Neurogastroenterol Motil; 2011 Feb 06; 23(2):155-60, e31. PubMed ID: 21087355
    [Abstract] [Full Text] [Related]

  • 19. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
    Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Nauclér E, Eklund S, Expo Study Investigators.
    Aliment Pharmacol Ther; 2005 Mar 15; 21(6):739-46. PubMed ID: 15771760
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.
    Fennerty MB, Johanson JF, Hwang C, Sostek M.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):455-63. PubMed ID: 15709997
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.